T1	Participants 68 104	adult respiratory distress syndrome.
T2	Participants 336 425	G-CSF group which received chemotherapy with G-CSF and historical controls without G-CSF.
T3	Participants 439 597	132 patients with hematological malignancy in complete remission without any main organ dysfunction who had been treated between April 1983 and December 1997.
T4	Participants 673 691	who received G-CSF
T5	Participants 715 849	There was no remarkable difference in the number of patients, gender, age, or distribution of primary diseases between the two groups.
